Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Kymera Therapeutics Inc KYMR

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

GlobeNewswire May 19, 2023

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

GlobeNewswire May 18, 2023

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire May 4, 2023

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

GlobeNewswire April 11, 2023

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire March 1, 2023

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

GlobeNewswire February 23, 2023

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

GlobeNewswire February 1, 2023

X-Chem and Kymera Expand Existing Partnership

Business Wire January 31, 2023

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

GlobeNewswire January 10, 2023

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

GlobeNewswire January 4, 2023

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

GlobeNewswire January 3, 2023

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi's Decision to Advance KT-474 into Phase 2 Clinical Trials

GlobeNewswire December 14, 2022

Preclinical Data from Kymera Therapeutics' Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

GlobeNewswire December 12, 2022

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2022

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

GlobeNewswire December 1, 2022

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire November 3, 2022

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

GlobeNewswire November 3, 2022

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

GlobeNewswire October 20, 2022

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

GlobeNewswire October 13, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

GlobeNewswire September 15, 2022